市场调查报告书
商品编码
1373362
血栓切除设备市场 - 按产品类型、按应用、最终用途 - 全球预测,2023-2032 年Thrombectomy Devices Market - By Product Type, By Application, By End-use - Global Forecast, 2023-2032 |
在持续的技术进步以及微创和高效设备不断发展的推动下,血栓切除设备市场规模从 2023 年到 2032 年将以 7.3% 的复合年增长率成长。
全球医疗保健支出不断增长,加上先进医疗技术的日益采用,正在促进医疗机构对最新、最有效的治疗方案的投资不断增加。此外,由于高度重视改善患者护理和治疗结果,医疗机构正在分配大量资源来采购最新的血栓切除设备,进一步促进市场扩张。
血栓切除设备产业分为产品类型、应用、最终用途和地区。
根据产品类型,预计2023 年至2032 年间,凝块抽取导管细分市场的市场规模将获得显着增长。这一增长可归因于凝块抽取导管提供有效、微创凝块清除解决方案的强大能力,以促进精确的凝块清除解决方案。以及在各种心血管和神经血管应用中的高效血栓提取。
此外,用于增强导航和可操作性的不断进步的技术进步将有助于该细分市场的成长。例如,2023 年 6 月,Penumbra 获得 FDA 批准推出其 Lightning Bolt 7 动脉血栓切除系统,该系统采用调节抽吸功能,透过压力感测器去除血栓。
预计在 2023 年至 2032 年间,血栓切除设备市场将见证神经血管血栓切除术应用领域的牵引。这是由于缺血性中风和动脉瘤等神经血管疾病的盛行率不断上升。随着人们越来越关注提高神经血管治疗的疗效和降低相关风险,对用于复杂的神经血管手术的先进血栓切除设备的需求激增。这可能会推动该细分市场的成长。
从地区来看,在医疗保健支出增加和心血管疾病发病率上升的推动下,欧洲血栓切除设备产业将在 2032 年实现强劲成长。根据世界卫生组织报告,欧盟每年发现超过600万例CVD病例,超过170万人死于循环系统疾病,约占总死亡人数的37%。对技术进步和创新医疗设备的采用的高度重视正在促进血栓切除术在临床环境中的广泛整合。此外,支持性的监管架构和有利的报销政策也鼓励欧洲国家采用血栓切除设备。
.3.2.2.1。严格规定
.3.2.2.2。产品成本高
Thrombectomy Devices Market size is poised to expand at 7.3% CAGR from 2023 to 2032, driven by the ongoing technological advancements along with the rising development of minimally invasive and efficient devices.
The growing healthcare expenditure worldwide coupled with the increasing adoption of advanced medical technologies is facilitating the rising investments in latest and most effective treatment options by healthcare facilities. Additionally, with the strong focus on enhancing patient care and outcomes, healthcare institutions are allocating significant resources to procure the latest thrombectomy devices, further fostering the market expansion.
The thrombectomy devices industry is segmented into product type, application, end-use, and region.
Based on product type, the market size from the clot extraction catheter segment is projected to gain significant traction between 2023 and 2032. The growth can be attributed to the strong ability of clot extraction catheters to provide effective and minimally invasive clot removal solutions for facilitating precise and efficient thrombus extraction in various cardiovascular and neurovascular applications.
Additionally, the rising technological advancements for enabling enhanced navigation and maneuverability will contribute to the segment growth. For instance, in June 2023, Penumbra received FDA approval for the launch of its Lightning Bolt 7 arterial thrombectomy system deployed with regulated aspiration to remove blood clots with pressure sensors.
Thrombectomy devices market is anticipated to witness traction from the neurovascular thrombectomy application segment between 2023 and 2032. This is attributed to the rising prevalence of neurovascular conditions, such as ischemic strokes and aneurysms. With the increasing focus on improving the efficacy of neurovascular treatments and reducing associated risks, there is surging demand for advanced thrombectomy devices for adoption in intricate neurovascular procedures. This is likely to propel the segment growth.
Regionally, Europe thrombectomy devices industry will record robust growth through 2032 driven by the increasing healthcare expenditure and the rising incidence of cardiovascular diseases. According to the WHO report, every year across the EU, more than 6 million cases of CVD are identified, and over 1.7 million people die from circulatory system disorders, accounting for around 37% of all fatalities. The strong emphasis on technological advancements and the adoption of innovative medical devices are facilitating the widespread integration of thrombectomy procedures in clinical settings. Moreover, supportive regulatory frameworks and favorable reimbursement policies are also encouraging the adoption of thrombectomy devices across European countries.